SCINNABIS

Science-based Medical Cannabis Products

Health Tech & Life Sciences
Non Active, Oct 2021 ceased to operate
Pre-Funding Rishon LeTsiyon, Israel Founded 2019
LinkedIn
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2019
Headcount
1-10
HQ
Rishon LeTsiyon, Israel
Sector
Health Tech & Life Sciences

About

SCINNABIS develops medical cannabis solutions. The company separates and re-integrates the active ingredients in cannabis to develop personalized medicine for specific medical indications. In so doing, SCINNABIS creates accurate, science-based products containing specific compositions to treat different medical indications.

Q&A

What is SCINNABIS's primary business focus?
SCINNABIS develops science-based medical cannabis products by separating and re-integrating active ingredients to create personalized medicine for specific medical indications.
When was SCINNABIS founded?
SCINNABIS was founded in July 2019.
What is the current status of SCINNABIS?
SCINNABIS is currently inactive and ceased to operate in October 2021.
Where is SCINNABIS headquartered?
SCINNABIS is headquartered in Rishon LeTsiyon, Israel.
Who are the co-founders of SCINNABIS?
The co-founders of SCINNABIS are Ben Peretz (Co-founder & CEO) and Moran Mazuz (Co-founder & CTO).
What is SCINNABIS's primary sector classification?
SCINNABIS's primary sector classification is Health Tech & Life Sciences.

Team · 2

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisDrugs Discovery & Development
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

treatmentspharma-companieschronic-patientspersonalized-medicineparentspharmaceuticalsnatural-active-ingredientscannabismedical-cannabis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)